Medication for Huntington's disease gets U.S. approval

08/17/2008 | Forbes · Calgary Herald (Alberta)

The FDA approved Prestwick Pharmaceuticals' Xenazine, making it the first medication for Huntington's disease to obtain U.S. clearance. The drug, which decreases levels of dopamine, is designed to suppress chorea -- involuntary body movements associated with the disease. Xenazine can cause depression or increase the risk of suicide in some patients, the FDA said.

View Full Article in:

Forbes · Calgary Herald (Alberta)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ